Close Menu

GenomeWeb

The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.

The firm will use the proceeds to advance its liquid biopsy early cancer detection assay CancerSEEK in an FDA registrational trial.

In more than a dozen new papers, ENCODE researchers reported on analyses of the human and mouse genomes, using new data types and additional tissues.

Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.

A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

In Science this week: chromatin accessibility of microglia during fetal development, and more.

The tumor microenvironment (TME) is comprised of an array of cell types, including immune and inflammatory cells, adipose cells, neuroendocrine cells, and cancer-associated fibroblasts. Additionally, blood and lymphatic vascular networks and extracellular matrix components create a diverse and multifaceted situation. Understanding how all of these elements interact requires the ability to distinguish individual cell types--something that is difficult to do using bulk cell approaches. Single cell gene expression analyses offer a high-resolution understanding of the TME.

Carrier screening to detect the presence of heritable genetic defects has been an important element of reproductive health strategies for over 50 years. Until recently, however, the practice has been restricted to a limited number of single-gene tests offered mainly to higher-risk individuals or populations based on race, ethnicity, or ancestry. But the landscape of carrier screening and its role in reproductive health are changing fast.